Imdevimab (REGN10987), a human monoclonal antibody designed to neutralize the SARS-CoV-2 virus responsible for COVID-19, demonstrates reduced efficacy against emerging COVID-19 variants. When combined with Casirivimab, it effectively reduces viral load and enhances disease management [1].
CAS Number:
[2415933-40-1]
Target:
SARS-CoV
* VAT and and shipping costs not included. Errors and price changes excepted
